secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001193125-24-156043
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Teva shareholders elect four directors, approve say-on-pay and auditor at annual meeting
--------------------------------------------------------------------------------

- Elected Prof. Varda Shalev to board through 2026; Rosemary Crane, Gerald Lieberman, Prof. Ronit Satchi-Fainaro through 2027.
- Non-binding advisory vote on executive compensation approved: 571,822,049 for vs 120,609,632 against.
- Shareholders recommended annual advisory vote on exec comp (one-year frequency) with 536,980,720 votes.
- Ratification of Kesselman & Kesselman (PwC) as independent auditor approved: 731,150,255 for, 30,335,560 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312524156043/0001193125-24-156043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312524156043/d841419d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-156043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer